SAR245408 (XL147)

SAR245408 (XL147) is an orally available inhibitor of phosphoinositide-3-kinase (PI3K). PI3K plays an important role in cell proliferation and survival, and activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy. Exelixis discovered SAR245408 internally and out-licensed the compound to Sanofi. SAR245408 has been evaluated by Sanofi as a single agent and in multiple combination regimens in a variety of cancer indications.